To systematically evaluate the short-term safety and efficacy of Shexiang Baoxin Pill（麝香保心丸）combined with dual antiplate therapy in the treatment of elderly female patients with acute myocardial infarction.

90 female patients with acute myocardial infarction were collected.They were divided into observation group（group A，45 cases）and control group（group B，45 cases）by random number table method.The observation group was treated with Shoxiang Baoxin Pill combined with dual antiplate therapy.The control group was treated with conventional dual antiplate therapy.Both groups received routine hospital treatment for 2 weeks and were discharged with symptoms improved.After discharge，they took medicine regularly according to the doctor´s advice.The data before treatment and one month after discharge was recorded respectively.The efficacy indicators were angina pectoris efficacy score，Herth hope scale and QLQ-C30（quality of life survey rating table）.The safety indicators included platelet count，P-D score（PRECISE-DAPT score，or prediction of bleeding complications in patients undergoing coronary stent implantation and subsequent dual antiplatelet therapy），liver function（alanine aminotransferase，aspartate aminotransferase），kidney function（creation），bleeding，recurrence of myocardial infarction，death and other adverse reactions.The clinical efficacy and safety of Shexiang Baoxin Pill combined with dual antiplate therapy in the treatment of elderly female patients with acute myocardial infarction were analyzed.

1.There were no significant differences in the values of alanine aminotransferase，aspartate aminotransferase，platelet or creatinine between the two groups before treatment（P>0.05）.After treatment，the observation group showed a decrease in alanine aminotransferase，while the control group showed a slight increase in alanine aminotransferase，with no statistically significant difference between the two groups（P>0.05）.After treatment，the control group showed a decrease in aspartate aminotransferase，while the observation group showed no significant change in aspartate aminotransferase，and there was no statistical difference between the two groups（P>0.05）.After treatment，the platelet count in both groups decreased，and there was no statistically significant difference between the two groups（P>0.05）.After treatment，the creatinine levels in both groups increased and there was no statistically significant difference between the two groups（P>0.05）.2.There was no statistical significance in QLQ-C30，angina pectoris score or Herth score between the two groups before treatment（P>0.05）.After treatment，the QLQ-C30 scores and angina pectoris scores of the two groups decreased significantly，the Herth scores of the control group decreased，and that of the observation group increased.The angina pectoris score of the observation group was significantly lower than that of the control group after treatment with statistical significance（P<0.05），but the QLQ-C30 score and Herth score after treatment had no statistical significance（P>0.05）.3.There was no statistical significance in PD scores of the two groups before treatment（P>0.05），and PD scores of the two groups after treatment were significantly decreased compared with those before treatment，and the score of the observation group was significantly better than that of the control group（P<0.05）.4.There was no significant difference in adverse events between the two groups（P>0.05）.

Shexiang Baoxin Pill combined with dual antiplate therapy can significantly reduce angina pectoris score and improve angina pectoris symptoms in the treatment of elderly female patients with myocardial infarction，and it is safe and effective，without increasing the risk of bleeding and the burden of liver and kidney.